Trial Profile
A Phase 1b Study of LY2157299 in Combination With Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan
- 03 Feb 2020 Status changed from active, no longer recruiting to completed.
- 02 Dec 2019 Planned End Date changed from 31 Dec 2019 to 25 Dec 2019.
- 02 Aug 2019 Planned End Date changed from 31 Oct 2019 to 31 Dec 2019.